Targeting uPA/uPAR in prostate cancer.

Abstract:

:Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite significant advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to secondary disease (metastases). The invasive ability of tumour cells plays a key role in CaP metastasis and is a major cause of treatment failure. Urokinase plasminogen activator (uPA) and its receptor (uPAR)-mediated signalling have been implicated in tumour cell invasion, survival, and metastasis in a variety of cancers including CaP. Both uPA and uPAR are expressed at much higher levels in CaP tissues than in benign and normal prostate tissues. They are used as diagnostic markers as well as therapeutic targets due to their aberrant and unique expression pattern during cancer progression. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Therefore, much effort is currently being directed toward targeting aberrant uPA or uPAR activity in CaP. This review summarizes some important new findings supporting the role of uPA/uPAR in CaP progression and establishing the potential therapeutic efficacy of uPA/uPAR-targeted therapies in CaP.

journal_name

Cancer Treat Rev

journal_title

Cancer treatment reviews

authors

Li Y,Cozzi PJ

doi

10.1016/j.ctrv.2007.06.003

subject

Has Abstract

pub_date

2007-10-01 00:00:00

pages

521-7

issue

6

eissn

0305-7372

issn

1532-1967

pii

S0305-7372(07)00076-X

journal_volume

33

pub_type

杂志文章,评审
  • An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

    abstract::Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.03.001

    authors: Pasello G,Ceresoli GL,Favaretto A

    更新日期:2013-02-01 00:00:00

  • Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: normal tissue dose constraints of the central nervous system.

    abstract::Single-fraction stereotactic radiosurgery (SRS) and hypofractionated stereotactic radiotherapy (SRT) are radiation planning and delivery techniques used for the treatment of intracranial and spine/spinal cord tumors and targets. For cranial SRS and SRT, critical normal tissues/structures include the brainstem, cranial...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.04.004

    authors: Milano MT,Usuki KY,Walter KA,Clark D,Schell MC

    更新日期:2011-11-01 00:00:00

  • Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy.

    abstract::Vinorelbine is a semi-synthetic vinca alkaloid that has been shown active in many tumour types and is currently registered for the treatment of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC). This agent has a generally favourable safety profile, and may be suitable for use in special populations s...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.12.008

    authors: Mano M

    更新日期:2006-04-01 00:00:00

  • Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.

    abstract:BACKGROUND:Radical cystectomy (RC) associated with pelvic lymph node dissection (PLND) is the most common local therapy in the management of non-metastatic muscle invasive bladder cancer (MIBC). Loco-regional recurrence (LRR), however, remains a common and important therapeutic challenge associated with poor oncologic ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.07.011

    authors: Sargos P,Baumann BC,Eapen L,Christodouleas J,Bahl A,Murthy V,Efstathiou J,Fonteyne V,Ballas L,Zaghloul M,Roubaud G,Orré M,Larré S

    更新日期:2018-11-01 00:00:00

  • Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications.

    abstract::In cancer biology angiogenesis plays a vital role in tumour growth and its subsequent metastatic potential. By targeting the angiogenic process, a new treatment strategy was added in the clinician's therapeutic armamentarium. On the other hand, numerous classic cytotoxic agents are currently considered as potential an...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.09.002

    authors: Soultati A,Mountzios G,Avgerinou C,Papaxoinis G,Pectasides D,Dimopoulos MA,Papadimitriou C

    更新日期:2012-08-01 00:00:00

  • Lymphatic spread, nodal count and the extent of lymphadenectomy in cancer of the colon.

    abstract::In colon cancer, the biological significance of lymphatic tumour spread remains a matter of debate, which impacts on related questions such as the ideal extent of lymphadenectomy and the prognostic significance of lymph node counts. Several lines of evidence suggest that metastasis to locoregional nodes occurs early a...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2013.09.013

    authors: Willaert W,Mareel M,Van De Putte D,Van Nieuwenhove Y,Pattyn P,Ceelen W

    更新日期:2014-04-01 00:00:00

  • Electrochemotherapy of chest wall breast cancer recurrence.

    abstract::Chest wall breast cancer recurrence after mastectomy is a disease difficult to treat. Its incidence varies between 5% and 30% in different subset of patients. When possible, radical surgical therapy represents the main treatment approach, however when the disease progresses and/or treatments are not successful, ulcera...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2011.07.006

    authors: Sersa G,Cufer T,Paulin SM,Cemazar M,Snoj M

    更新日期:2012-08-01 00:00:00

  • Fertility preservation in women with borderline ovarian tumours.

    abstract::Borderline ovarian tumours (BOT) may occur in young women and have an excellent survival rate. Therefore, there is the obligation to put emphasis on fertility preservation in affected women. On the other hand, it has also been underlined that the disease should be managed with caution because these tumours can relapse...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.06.010

    authors: Mangili G,Somigliana E,Giorgione V,Martinelli F,Filippi F,Petrella MC,Candiani M,Peccatori F

    更新日期:2016-09-01 00:00:00

  • Circulating tumor cells in colorectal cancer patients.

    abstract::The availability of sensitive methods has allowed the detailed study of circulating tumor cells only recently. Evolving evidence support the prognostic and predictive role of these cells in patients affected by several solid tumors, including colorectal cancer. Ongoing studies are aimed at confirming that the molecula...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2012.12.007

    authors: Torino F,Bonmassar E,Bonmassar L,De Vecchis L,Barnabei A,Zuppi C,Capoluongo E,Aquino A

    更新日期:2013-11-01 00:00:00

  • Targeted therapies in advanced differentiated thyroid cancer.

    abstract::Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10 years. Although most patients with this disease have an excellent prognosis, a subset develops a more aggressive disease phenotype refractory to conventional therapies. Until recently, ther...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2015.06.002

    authors: Carneiro RM,Carneiro BA,Agulnik M,Kopp PA,Giles FJ

    更新日期:2015-09-01 00:00:00

  • Neoadjuvant endocrine therapy in breast cancer.

    abstract::The use of endocrine therapy is well established as a primary treatment for locally advanced breast cancer. However, despite the current popularity of neoadjuvant chemotherapy for operable tumours, there is relatively little published evidence for pre-operative endocrine therapy in operable disease, particularly outsi...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2006.10.003

    authors: Beresford MJ,Ravichandran D,Makris A

    更新日期:2007-02-01 00:00:00

  • Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review.

    abstract:PURPOSE:To evaluate the existing evidence regarding the long-term risk of cardiovascular disease (CVD) after radiotherapy for childhood cancer. PATIENTS AND METHODS:MEDLINE and EMBASE were searched for articles reporting on radiation-induced CVD after childhood cancer published between 1966 and October 2002. Informati...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2005.03.008

    authors: van der Pal HJ,van Dalen EC,Kremer LC,Bakker PJ,van Leeuwen FE

    更新日期:2005-05-01 00:00:00

  • RAF signaling in neuroendocrine neoplasms: from bench to bedside.

    abstract::Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2014.06.009

    authors: Fazio N,Abdel-Rahman O,Spada F,Galdy S,De Dosso S,Capdevila J,Scarpa A

    更新日期:2014-09-01 00:00:00

  • Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials.

    abstract:BACKGROUND:The colony-stimulating factors (CSFs) are widely utilized to prevent neutropenic complications in both adults and children, but randomized controlled trials in the pediatric setting have reported varied results. A systematic review of the literature and meta-analysis were conducted to definitively assess the...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ctrv.2006.03.002

    authors: Wittman B,Horan J,Lyman GH

    更新日期:2006-06-01 00:00:00

  • Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.

    abstract::In metastatic colorectal cancer (mCRC), fluorouracil-based combination therapy with oxaliplatin or irinotecan is the mainstay of first-line treatment. Patient survival has been significantly improved with the introduction of monoclonal antibodies against VEGF (bevacizumab), VEGFR2 (ramucirumab) or EGFR (cetuximab or p...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.10.006

    authors: Sartore-Bianchi A,Siena S,Tonini G,Bardelli A,Santini D

    更新日期:2016-12-01 00:00:00

  • Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.

    abstract::Lung cancer has the highest frequency of brain dissemination compared to all other solid tumours. Classical treatment options such as brain irradiation have started to be questioned due to lack of survival benefit and risk for severe side effects. Oncogenic driven tumours have the highest frequency of brain disseminat...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2017.02.004

    authors: Tsakonas G,De Petris L,Ekman S

    更新日期:2017-03-01 00:00:00

  • Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review.

    abstract::Bone-seeking radionuclides, such as Sr-89, Sm-153, and Re-186, have been shown to have an effect on pain from bone metastasis in prostate cancer. The effect on bone pain in other cancer types, including breast cancer, remains unclear. The purpose of the study was to perform a systematic review of the use of radioisoto...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,随机对照试验,评审

    doi:10.1016/j.ctrv.2011.05.008

    authors: Christensen MH,Petersen LJ

    更新日期:2012-04-01 00:00:00

  • Megestrol acetate: clinical experience.

    abstract::The use of megestrol acetate in treatment of malignancy (endometrial carcinoma, ovarian cancer, prostate cancer, breast cancer, renal cell carcinoma, malignant melanoma), endometrial hyperplasia, benign prostatic hypertrophy, contraception, anorexia, cachexia and weight loss is reviewed, concluding with a toxicity pro...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/0305-7372(89)90004-2

    authors: Schacter L,Rozencweig M,Canetta R,Kelley S,Nicaise C,Smaldone L

    更新日期:1989-03-01 00:00:00

  • Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.

    abstract::Given its role in cellular metabolism, the proteasome could prove to be a critical target that can be exploited in treating cancer. In preclinical studies, several mechanisms for bortezomib's activity in multiple myeloma cells have been identified (e.g., NF-kappaB inhibition); antitumor activity with bortezomib has be...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00079-3

    authors: Cusack JC

    更新日期:2003-05-01 00:00:00

  • Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?

    abstract::Approximately 1% of women in the United States will be diagnosed with epithelial ovarian cancer (EOC) during their lifetime. It is most likely to present at a more advanced stage, requiring aggressive therapeutic measures, and most women will succumb to this illness. Due to advancements in therapy, the oncology commun...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2018.06.001

    authors: DiSilvestro P,Alvarez Secord A

    更新日期:2018-09-01 00:00:00

  • Is there a role for a specialized follow-up clinic for survivors of pediatric cancer?

    abstract::Due to advances in chemotherapy and supportive care, greater than 70% of patients with childhood cancer will survive 5 years. However, there are long-term physiological and psychological sequelae of these treatments that may not manifest until pediatric survivors are into adulthood. Various studies done in the long-te...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.02.014

    authors: Prasad PK,Bowles T,Friedman DL

    更新日期:2010-06-01 00:00:00

  • Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.

    abstract::Bladder cancer is one of the leading causes of death in Europe and the United States. About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy. In the setting of metastatic disease, use of cisplatin-based regime...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2016.09.018

    authors: Morales-Barrera R,Suárez C,de Castro AM,Racca F,Valverde C,Maldonado X,Bastaros JM,Morote J,Carles J

    更新日期:2016-11-01 00:00:00

  • Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment.

    abstract::When focusing on heart disease, most available studies split the two different parts of the adjuvant treatment, i.e., systemic therapies and radiation therapy, making it difficult to implement efficient strategies for preventing treatment-induced cardiac toxicity. This paper reviews the current understanding of treatm...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.08.007

    authors: Chargari C,Kirov KM,Bollet MA,Magné N,Védrine L,Cremades S,Beuzeboc P,Fourquet A,Kirova YM

    更新日期:2011-06-01 00:00:00

  • Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

    abstract::Tissue hypoxia occurs where there is an imbalance between oxygen supply and consumption. Hypoxia occurs in solid tumours as a result of an inadequate supply of oxygen, due to exponential cellular proliferation and an inefficient vascular supply. It is an adverse prognostic indicator in cancer as it is associated with ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/s0305-7372(03)00003-3

    authors: Shannon AM,Bouchier-Hayes DJ,Condron CM,Toomey D

    更新日期:2003-08-01 00:00:00

  • In vivo antitumor activity of ilmofosine.

    abstract::Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral ...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(90)90055-k

    authors: Herrmann DB,Pahlke W,Opitz HG,Bicker U

    更新日期:1990-09-01 00:00:00

  • Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients.

    abstract::Thirty-one patients with metastatic renal cell carcinoma were seen at the Centre Léon Bérard from October 1987 to October 1988. According to our protocol, 11 were excluded leaving 20 in the study. The median age was 55 years (range 36 to 79 years). The median number of metastases was 9 (range 2 to 29) and the median n...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(89)90028-5

    authors: Philip T,Mercatello A,Negrier S,Philip I,Rebattu P,Kaemmerlin P,Gaspard M,Tognier E,Combaret V,Bijmann JT

    更新日期:1989-06-01 00:00:00

  • Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis.

    abstract:INTRODUCTION:Identification of membrane proteins expressed exclusively on tumor cells is a goal for cancer drug development. The receptor tyrosine kinase-like orphan receptor type 1 and 2 (ROR1/2), are type-I transmembrane proteins expressed in cancer but not in adult normal tissue. Here, we explore the prognostic role...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ctrv.2019.05.006

    authors: Saleh RR,Antrás JF,Peinado P,Pérez-Segura P,Pandiella A,Amir E,Ocaña A

    更新日期:2019-07-01 00:00:00

  • Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.

    abstract::The French Epirubicin Study Group undertook a retrospective study to evaluate the response rate at relapse, time to treatment failure, and overall survival according to previous CMF-type adjuvant chemotherapy in patients who had taken part in two successive clinical trials. The statistical significance of the comparis...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章

    doi:10.1016/0305-7372(93)90004-b

    authors: Bonneterre J,Mercier M

    更新日期:1993-04-01 00:00:00

  • New developments in arc radiation therapy: a review.

    abstract::Arc therapies have gained widespread clinical interest in radiation oncology over the past decade. Arc therapies have several potential advantages over standard techniques such as intensity-modulated radiation therapy, with implications for patients, administrators, and oncologists. This review focuses on the rational...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1016/j.ctrv.2010.01.004

    authors: Palma DA,Verbakel WF,Otto K,Senan S

    更新日期:2010-08-01 00:00:00

  • New approaches to the systemic treatment of melanoma.

    abstract::Metastatic melanoma is an incurable condition with a median survival of about 6 months. Chemotherapy can result in objective tumour responses but only in a minority of cases and remissions are short-lived, 3-6 months. DTJC is the most active single agent with response rates of 15-20% and although combination chemother...

    journal_title:Cancer treatment reviews

    pub_type: 杂志文章,评审

    doi:10.1053/ctrv.1999.0138

    authors: Chowdhury S,Vaughan MM,Gore ME

    更新日期:1999-10-01 00:00:00